Market closed
Merus/$MRUS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
201
Website
Merus Metrics
BasicAdvanced
$2.9B
Market cap
-
P/E ratio
-$3.98
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$2.9B
Beta
1.09
52-week high
$61.61
52-week low
$25.83
Average daily volume
639K
Financial strength
Current ratio
8.321
Quick ratio
7.944
Long term debt to equity
1.32
Total debt to equity
1.571
Management effectiveness
Return on assets (TTM)
-21.59%
Return on equity (TTM)
-44.60%
Valuation
Price to revenue (TTM)
71.651
Price to book
4.07
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
-16.366
Growth
Revenue change (TTM)
-21.33%
Earnings per share change (TTM)
9.59%
3-year revenue growth (CAGR)
-6.11%
3-year earnings per share growth (CAGR)
20.96%
What the Analysts think about Merus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Merus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merus News
AllArticlesVideos
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
GlobeNewsWire·5 days ago
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
GlobeNewsWire·2 weeks ago
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $2.9B as of December 22, 2024.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of December 22, 2024.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.